Osel
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
320 Logue Ave # 644, Mountain View, Cali...Phone Number
(650) 964-4679Website
www.oselinc.comRevenue
<$5 MillionIndustry
About Osel
Osel Inc. is a clinical-stage biopharma company focused on pioneering live biotherapeutic products (LBPs) aimed at improving health by harnessing the microbiome. The company is particularly active in oncology, with ongoing clinical trials for its lead candidate, MO-03, which is being tested in combination with standard immuno-oncology regimens for advanced renal cell carcinoma. Osel also addresses women's health and has a pipeline of innovative therapies designed to restore health through microbiome modulation. Their intended clients include patients with advanced cancer and other health conditions that can benefit from microbiome-based therapies.Explore more
Osel Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Osel
Compare insights from companies similar to Osel, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Osel Tech Stack
A closer look at the technologies used by Osel
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Osel
Sign Up For FreeTo access detailed company insights
Osel Inc. is a clinical-stage biopharma company focused on pioneering live biotherapeutic products (LBPs) aimed at improving health by harnessing the microbiome. The company is particularly active in oncology, with ongoing clinical trials for its lead candidate, MO-03, which is being tested in combination with standard immuno-oncology regimens for... Read More
